KL002
/ Kanglin Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 31, 2023
Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Metastases • New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 1
Of
1
Go to page
1